» Articles » PMID: 34473060

Understanding Patterns of HIV Multi-drug Resistance Through Models of Temporal and Spatial Drug Heterogeneity

Overview
Journal Elife
Specialty Biology
Date 2021 Sep 2
PMID 34473060
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-drug therapies have transformed HIV from a fatal condition to a chronic one. These therapies should prevent HIV drug resistance evolution, because one or more drugs suppress any partially resistant viruses. In practice, such therapies drastically reduced, but did not eliminate, resistance evolution. In this article, we reanalyze published data from an evolutionary perspective and demonstrate several intriguing patterns about HIV resistance evolution - resistance evolves (1) even after years on successful therapy, (2) sequentially, often via one mutation at a time and (3) in a partially predictable order. We describe how these observations might emerge under two models of HIV drugs varying in space or time. Despite decades of work in this area, much opportunity remains to create models with realistic parameters for three drugs, and to match model outcomes to resistance rates and genetic patterns from individuals on triple-drug therapy. Further, lessons from HIV may inform other systems.

Citing Articles

Dynamic collateral sensitivity profiles highlight opportunities and challenges for optimizing antibiotic treatments.

Maltas J, Huynh A, Wood K PLoS Biol. 2025; 23(1):e3002970.

PMID: 39774800 PMC: 11709278. DOI: 10.1371/journal.pbio.3002970.


Patterns of HIV-1 Drug Resistance Observed Through Geospatial Analysis of Routine Diagnostic Testing in KwaZulu-Natal, South Africa.

Gounder L, Khan A, Manasa J, Lessells R, Tomita A, Pillay M Viruses. 2024; 16(10).

PMID: 39459966 PMC: 11512327. DOI: 10.3390/v16101634.


Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study.

Marcelin A, Soulie C, Wirden M, Barriere G, Durand F, Charpentier C J Antimicrob Chemother. 2024; 80(1):95-101.

PMID: 39436753 PMC: 11695916. DOI: 10.1093/jac/dkae377.


Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs.

Schmidlin K, Apodaca S, Newell D, Sastokas A, Kinsler G, Geiler-Samerotte K Elife. 2024; 13.

PMID: 39255191 PMC: 11386965. DOI: 10.7554/eLife.94144.


Modelling HIV-1 control and remission.

Vemparala B, Chowdhury S, Guedj J, Dixit N NPJ Syst Biol Appl. 2024; 10(1):84.

PMID: 39117718 PMC: 11310323. DOI: 10.1038/s41540-024-00407-8.


References
1.
Thompson C, Bokhart M, Sykes C, Adamson L, Fedoriw Y, Luciw P . Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Antimicrob Agents Chemother. 2015; 59(5):2944-8. PMC: 4394831. DOI: 10.1128/AAC.04952-14. View

2.
Gunthard H, Calvez V, Paredes R, Pillay D, Shafer R, Wensing A . Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis. 2018; 68(2):177-187. PMC: 6321850. DOI: 10.1093/cid/ciy463. View

3.
Eron J, Benoit S, Jemsek J, MacArthur R, SantAna J, Quinn J . Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995; 333(25):1662-9. DOI: 10.1056/NEJM199512213332502. View

4.
Bershteyn A, Eckhoff P . A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns. BMC Syst Biol. 2013; 7:11. PMC: 3643872. DOI: 10.1186/1752-0509-7-11. View

5.
Hoffmann C, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson R . Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009; 49(12):1928-35. PMC: 2789416. DOI: 10.1086/648444. View